Repertaxin L-lysine salt New
Data Sheet
For research use only. Not for human use.
Get Quotation Now* Required Fields.
Please complete the form below and you will get the price list in 1 minute.
* Required Fields.
Please complete the form below and we will contact you shortly.
* Required Fields.
Please complete the form below and we will contact you shortly.
| CAS No. | 266359-93-7 | Cat. No. | BCP30625 |
| Name | Repertaxin L-lysine salt | ||
| Synonyms | Reparixin L-lysine；Repertaxin L-lysine salt；(2S)-2,6-diaminohexanoic acid;(2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; | ||
| SMILES | CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C.C(CCN)CC(C(=O)O)N | ||
| Chemical Name | |||
| Formula | C14H21NO3S.C6H14N2O2 | M. Wt | 429.58 |
| Purity | 98% | Storage | Store at 4-8°C |
| Description | The efficacy of RPX (tested in a wide range of concentrations (1-1000 nM)) was lower in cells expressing Ile43Val CXCR1 mutant (IC50 values of 0.0056 and 0.08 uM for CXCR1 weight and CXCR1 Ile43Val, respectively). Treatment with reparixin significantly counteracts secondary degeneration by reducing oligodendrocyte apoptosis, migration to the injury site of neutrophils and ED-1-positive cells. The best beneficial outcome of reparixin treatment required 7-day administration either by i.p. route (15 mg/kg) or subcutaneous infusion via osmotic pumps (10 mg/kg), reaching a steady blood level of 8 microg/ml. Reparixin effectively decreased systolic blood pressure and increased the blood flow. The thoracic aorta wall thickness was significantly decreased in SHR-R compared to SHR-N. Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and reperfusion. Myeloperoxidase activity and IL-iβ were reduced in the reparixin-treated group. Histological analysis revealed that ischemic injury was also attenuated by reparixin pre-treatment. | ||
Recommend Products
More >
-
ACT-1004-1239
Cat. No.：BCP46165
No.：2178049-58-4
Product Details -
-
-
-
VUF11207 fumarate
Cat. No.：BCP34887
No.：1785665-61-3
Product Details -
-
-
-
Mavorixafor trihydrochloride
Cat. No.：BCP32916
No.：2309699-17-8
Product Details -
BX471 hydrochloride
Cat. No.：BCP32594
No.：288262-96-4
Product Details -
-
-
Baohuoside I
Cat. No.：BCP30977
No.：113558-15-9
Product Details -
-
-
-
Elubrixin hydrochloride
Cat. No.：BCP23554
No.：688763-65-7
Product Details -
Mavorixafor hydrochloride
Cat. No.：BCP26048
No.：880549-30-4
Product Details -
-
Vimnerixin
Cat. No.：BCP24003
No.：1418112-77-2
Product Details
Tags:Repertaxin L-lysine salt supplier,Repertaxin L-lysine salt purchase,Repertaxin L-lysine salt manufacturer,Repertaxin L-lysine salt distributor,Repertaxin L-lysine salt cost,Repertaxin L-lysine salt buy,Repertaxin L-lysine salt for sale